Cargando…
Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy
BACKGROUND: Spinal muscular atrophy (SMA) results from a loss-of-function mutation in the SMN1 gene. SMA patients suffer progressive motor disability, although no intellectual impairments have been described. Three drugs have been recently approved by the US Food and Drug Administration (FDA) and th...
Autores principales: | Ngawa, Magali, Dal Farra, Fabian, Marinescu, Andrei-Dan, Servais, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944336/ https://www.ncbi.nlm.nih.gov/pubmed/36846472 http://dx.doi.org/10.1177/17562864231154335 |
Ejemplares similares
-
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England
por: Weidlich, Diana, et al.
Publicado: (2023) -
Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review
por: Aragon-Gawinska, Karolina, et al.
Publicado: (2023) -
Spinal Muscular Atrophy Diagnosed by Newborn Screening
por: Lopez-Chacon, Matias, et al.
Publicado: (2019) -
Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
por: Dangouloff, Tamara, et al.
Publicado: (2019) -
Interventions for spinal muscular atrophy: an impetus for newborn screening
Publicado: (2021)